Nanotechnology Now - Press Release: University of Virginia Cancer Center and Keystone Nano Announce Start of Clinical Testing of Ceramide Nanoliposome for Treatment of Solid Tumors

Home > Press > University of Virginia Cancer Center and Keystone Nano Announce Start of Clinical Testing of Ceramide Nanoliposome for Treatment of Solid Tumors

Abstract:
University of Virginia Cancer Center and Keystone Nano, Inc. announce that clinical testing has been initiated at UVA on a new potential cancer therapy. The study is a Phase I clinical trial to assess Ceramide NanoLiposome in the treatment of solid tumors.

University of Virginia Cancer Center and Keystone Nano Announce Start of Clinical Testing of Ceramide Nanoliposome for Treatment of Solid Tumors

Charlottesville, VA and State College, PA | Posted on August 28th, 2017

Dr. Mark Kester, Keystone Nano’s Chief Medical Officer, Director of UVA’s NanoSTAR program and the original developer of Ceramide NanoLiposome, remarked: “We are excited to investigate the effectiveness of this potential therapy in patients with solid tumors.” Mr. Jeff Davidson, Keystone Nano’s CEO remarked: “Our company is pleased to be working with the University of Virginia Cancer Center and look forward to the testing of this new therapy.”
Ceramide is a biologically active lipid that is being examined as a potential treatment for liver cancer, as well as in breast cancer, leukemia and pancreatic cancer. Ceramide NanoLiposome seeks to kill cancer cells while leaving normal cells alone, providing treatment without undue toxicity.

The Phase I portion of the trial will recruit patients with solid tumors to examine dosing and safety. The Phase II component of the trial is expected to focus on Liver Cancer, which kills approximately 27,000 people in the United States and 700,000 worldwide each year. There is currently no effective therapy for this disease. Keystone Nano was recently awarded orphan drug status for the treatment of liver cancer with ceramides in the United States.

####

About Keystone Nano
Based in State College KN is working at the interface between nanotechnology and medicine. In addition to developing Ceramide NanoLiposome, the company is working on additional products using NanoJackets for RNA delivery.

For more information, please click here

Contacts:
eff Sirianni
Managing Member
Monarch Solutions, LLC
Ashburn, VA 20147
Mobile: (703) 728.6837
www.Monarchsls.com

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark: